<DOC>
	<DOC>NCT01046097</DOC>
	<brief_summary>The purpose of this post-marketing surveillance study is to evaluate the safety of Synflorix™ when administered according to the local Prescribing Information to healthy Filipino infants.</brief_summary>
	<brief_title>Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects who the investigator believes that their parents/Legally Acceptable Representative(s) (LAR(s)) can and will comply with the requirements of the protocol. Filipino male or female subjects whose age at the first vaccination with Synflorix™ in this PMS should not be less than 6 weeks of age. Filipino male or female subjects who enter the PMS at the second dose should not be less than 10 weeks of age. Filipino male or female subjects who enter the PMS at the third dose should not be less than 14 weeks of age. Filipino male or female subjects who enter the PMS at the booster dose (i.e. if they have received Synflorix™ in the previous dose/s outside the PMS) should not be less than 10 months of age. The time interval between the primary vaccination and booster dose should be at least 6 months. For the booster dose, subjects who received PCV7/13 or Synflorix™ in their primary vaccination series will be allowed to take part in the PMS. Written and signed informed consent obtained from the parents/LAR(s) of the child. Where parents/LAR(s) are illiterate, the consent form will be countersigned by a witness. Free of obvious health problems as established by medical history and clinical examination before entering into the study. Acute disease and/or fever at the time of vaccine administration. Fever is defined as temperature ≥ 37.5°C (99.5°F) on axillary, infrared or tympanic setting. Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine. History of chronic condition(s) requiring treatment such as cancer or autoimmune diseases. Hypersensitivity to latex (found in syringetip cap and plunger). Any contraindications as stated in the Prescribing Information.</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
</DOC>